Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tempest Therapeutics ( (TPST) ) just unveiled an announcement.
On May 19, 2026, Tempest Therapeutics received a deficiency notice from Nasdaq after reporting stockholders’ equity of $822,000 as of March 31, 2026, far below the $2.5 million minimum required for continued listing on the Nasdaq Capital Market, and it also failed to meet alternative market value and net income standards. The notice did not immediately affect its listing, and Tempest has until July 6, 2026, to submit a compliance plan, while on May 22, 2026, the company also informed Nasdaq that resignations from its board would leave it out of compliance with majority independent director and key board committee requirements, raising additional governance and listing risks.
Tempest’s equity shortfall and governance gaps highlighted growing pressure on its financial stability and corporate oversight, potentially heightening uncertainty for investors as it works to regain compliance within Nasdaq’s allowed timeframes. The company’s intention to submit a remediation plan and consider further options signaled an effort to preserve its exchange listing despite mounting regulatory and operational challenges.
The most recent analyst rating on (TPST) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.
Spark’s Take on TPST Stock
According to Spark, TipRanks’ AI Analyst, TPST is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses/cash burn, and a sharply weakened balance sheet with high leverage). Technicals are only neutral with modest short-term improvement but a still weak longer-term trend. Positive clinical-data headlines help the outlook, but near-term funding/dilution risk remains a major constraint.
To see Spark’s full report on TPST stock, click here.
More about Tempest Therapeutics
Tempest Therapeutics, Inc. is a biotechnology company focused on developing novel cancer therapies. The company operates in the biopharmaceutical sector, targeting oncology indications with experimental drug candidates aimed at improving outcomes for patients with difficult-to-treat tumors.
Average Trading Volume: 197,990
Technical Sentiment Signal: Sell
Current Market Cap: $27.54M
See more insights into TPST stock on TipRanks’ Stock Analysis page.